Date: 2016-02-09
Type of information: Recruitment of the first patient
phase: 1
Announcement: recruitment of the first patient
Company: Ziopharm Oncology (USA - MA)
Product: CAR-T cell therapy modified using the Sleeping Beauty system
Action
mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy. The Sleeping Beauty transposon-transposase is a non-viral system for introducing genes encoding T-cell receptors and chimeric antigen receptors into lymphocytes that was exclusively licensed to Ziopharm and its collaboration partner, Intrexon, through an agreement with the MD Anderson Cancer Center.
Disease: advanced lymphoid malignancies
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On February 9, 2016, Ziopharm Oncology announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in patients with advanced lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells.
The second-generation Sleeping Beauty CAR+ T cells employ a revised CAR construct designed to improve persistence and anti-tumor response over the first generation therapy. Additionally, this investigational treatment is independent of HSCT. This trial is being conducted at MD Anderson.
